BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 26178291)

  • 21. Capsaicin: a novel radio-sensitizing agent for prostate cancer.
    Venier NA; Colquhoun AJ; Sasaki H; Kiss A; Sugar L; Adomat H; Fleshner NE; Klotz LH; Venkateswaran V
    Prostate; 2015 Feb; 75(2):113-25. PubMed ID: 25307418
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Use of miR‑145 and testicular nuclear receptor 4 inhibition to reduce chemoresistance to docetaxel in prostate cancer.
    Zhu J; Qin P; Cao C; Dai G; Xu L; Yang D
    Oncol Rep; 2021 Mar; 45(3):963-974. PubMed ID: 33650661
    [TBL] [Abstract][Full Text] [Related]  

  • 23. RNA-seq profiling of a radiation resistant and radiation sensitive prostate cancer cell line highlights opposing regulation of DNA repair and targets for radiosensitization.
    Young A; Berry R; Holloway AF; Blackburn NB; Dickinson JL; Skala M; Phillips JL; Brettingham-Moore KH
    BMC Cancer; 2014 Nov; 14():808. PubMed ID: 25369795
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The prognostic value of ribonucleotide reductase small subunit M2 in predicting recurrence for prostate cancers.
    Huang Y; Liu X; Wang YH; Yeh SD; Chen CL; Nelson RA; Chu P; Wilson T; Yen Y
    Urol Oncol; 2014 Jan; 32(1):51.e9-19. PubMed ID: 24360663
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Constitutive mRNA expression of DNA repair-related genes as a biomarker for clinical radio-resistance: A pilot study in prostate cancer patients receiving radiotherapy.
    Hümmerich J; Werle-Schneider G; Popanda O; Celebi O; Chang-Claude J; Kropp S; Mayer C; Debus J; Bartsch H; Schmezer P
    Int J Radiat Biol; 2006 Aug; 82(8):593-604. PubMed ID: 16966187
    [TBL] [Abstract][Full Text] [Related]  

  • 26. External beam radiotherapy (EBRT) suppressed prostate stem cell antigen (PSCA) mRNA expression in clinically localized prostate cancer.
    Zhigang Z; Wenlu S
    Prostate; 2007 May; 67(6):653-60. PubMed ID: 17342746
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neoadjuvant hormonal therapy use and the risk of death in men with prostate cancer treated with brachytherapy who have no or at least a single risk factor for coronary artery disease.
    Nanda A; Chen MH; Moran BJ; Braccioforte MH; Dosoretz D; Salenius S; Katin M; Ross R; D'Amico AV
    Eur Urol; 2014 Jan; 65(1):177-85. PubMed ID: 22981136
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Effect of downregulation of prostate cancer antigen-1 expression on malignant biological behavior of prostate cancer LNCaP cells].
    Liu BQ; Wang YK; Wu YD; Wei JX; Li X
    Zhonghua Zhong Liu Za Zhi; 2013 Nov; 35(11):828-32. PubMed ID: 24447480
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The prognostic impact of tumour NSD2 expression in advanced prostate cancer.
    Stangl-Kremser J; Lemberger U; Hassler MR; Garstka N; Grubmüller B; Haitel A; Enikeev DV; Glybochko PV; Kramer G; Susani M; Shariat SF
    Biomarkers; 2020 May; 25(3):268-273. PubMed ID: 32091270
    [No Abstract]   [Full Text] [Related]  

  • 30. Y-box binding protein-1 promotes castration-resistant prostate cancer growth via androgen receptor expression.
    Shiota M; Takeuchi A; Song Y; Yokomizo A; Kashiwagi E; Uchiumi T; Kuroiwa K; Tatsugami K; Fujimoto N; Oda Y; Naito S
    Endocr Relat Cancer; 2011 Aug; 18(4):505-17. PubMed ID: 21652770
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Golgi phosphoprotein 3 expression predicts poor prognosis in patients with prostate cancer undergoing radical prostatectomy.
    Zhang L; Guo F; Gao X; Wu Y
    Mol Med Rep; 2015 Jul; 12(1):1298-304. PubMed ID: 25760033
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic significance of p53 nuclear accumulation in localized prostate cancer treated with radical prostatectomy.
    Quinn DI; Henshall SM; Head DR; Golovsky D; Wilson JD; Brenner PC; Turner JJ; Delprado W; Finlayson JF; Stricker PD; Grygiel JJ; Sutherland RL
    Cancer Res; 2000 Mar; 60(6):1585-94. PubMed ID: 10749127
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic factors in prostate cancer.
    Stattin P
    Scand J Urol Nephrol Suppl; 1997; 185():1-46. PubMed ID: 9249905
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Transactivation of the proximal promoter of human oxytocin gene by TR4 orphan receptor.
    Wang CP; Lee YF; Chang C; Lee HJ
    Biochem Biophys Res Commun; 2006 Dec; 351(1):204-8. PubMed ID: 17054912
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cortactin is associated with tumour progression and poor prognosis in prostate cancer and SIRT2 other than HADC6 may work as facilitator in situ.
    Hou H; Chen W; Zhao L; Zuo Q; Zhang G; Zhang X; Wang H; Gong H; Li X; Wang M; Wang Y; Li X
    J Clin Pathol; 2012 Dec; 65(12):1088-96. PubMed ID: 22944623
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inverse relationship between PSA and IL-8 in prostate cancer: an insight into a NF-κB-mediated mechanism.
    Xu Y; Fang F; St Clair DK; St Clair WH
    PLoS One; 2012; 7(3):e32905. PubMed ID: 22403723
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunohistochemical detection of tyrosine phosphatase SHP-1 predicts outcome after radical prostatectomy for localized prostate cancer.
    Tassidis H; Brokken LJ; Jirström K; Ehrnström R; Pontén F; Ulmert D; Bjartell A; Härkönen P; Wingren AG
    Int J Cancer; 2010 May; 126(10):2296-307. PubMed ID: 19795453
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Early salvage radiation therapy does not compromise cancer control in patients with pT3N0 prostate cancer after radical prostatectomy: results of a match-controlled multi-institutional analysis.
    Briganti A; Wiegel T; Joniau S; Cozzarini C; Bianchi M; Sun M; Tombal B; Haustermans K; Budiharto T; Hinkelbein W; Di Muzio N; Karakiewicz PI; Montorsi F; Van Poppel H
    Eur Urol; 2012 Sep; 62(3):472-87. PubMed ID: 22633803
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Best practices recommendations in the application of immunohistochemistry in the prostate: report from the International Society of Urologic Pathology consensus conference.
    Epstein JI; Egevad L; Humphrey PA; Montironi R;
    Am J Surg Pathol; 2014 Aug; 38(8):e6-e19. PubMed ID: 25029122
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Heat shock protein expression independently predicts clinical outcome in prostate cancer.
    Cornford PA; Dodson AR; Parsons KF; Desmond AD; Woolfenden A; Fordham M; Neoptolemos JP; Ke Y; Foster CS
    Cancer Res; 2000 Dec; 60(24):7099-105. PubMed ID: 11156417
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.